term peptide FAQ

Discard the vial. Selank amidate undergoes hydrolytic peptide bond cleavage at room temperature (20–25°C) at roughly five times the rate observed at 4°C. An eight-hour overnight excursion can cause 10–15% potency loss. The degradation products (truncated peptide fragments) remain in solution and are invisible to visual inspection, which means you cannot verify remaining potency without HPLC analysis. Using a partially degraded solution introduces uncontrolled variability into your protocol that makes data interpretation unreliable.

You can't extend the 28-day window without accepting potency loss and contamination risk. The bacteriostatic agent (0.9% benzyl alcohol) loses antimicrobial efficacy after four weeks, and peptide hydrolysis continues regardless of bacterial presence. If your research protocol requires longer timelines, reconstitute smaller volumes in separate vials and stagger reconstitution dates. For example, reconstitute 1mg every two weeks rather than 3mg at once. Alternatively, explore freeze-dried aliquoting: some researchers divide lyophilised powder into smaller vials before adding water, allowing precise single-use reconstitution. This requires sterile technique and typically isn't practical outside professional lab settings.

Check for condensation inside the vials and on the packaging. If the lyophilised peptides remained below 0°C throughout the outage, they're likely still viable. Lyophilised compounds tolerate brief temperature increases as long as they don't reach the melting point of residual moisture. If condensation is present, the vials warmed above freezing, and water re-entered the system. Contact the supplier to discuss replacement or potency testing. For reconstituted vials stored in the refrigerator during a power outage, check the internal fridge temperature. If it stayed below 10°C, use the peptides within 7 days instead of the full 28-day window. If the temperature exceeded 10°C for more than 2 hours, discard them.

Lyophilised LL-37 tolerates short-term ambient exposure (up to 7 days at 20–25°C) if the vial remained sealed and desiccated. Examine the desiccant packet: if it's saturated (colour change from blue to pink for silica gel), moisture infiltration occurred and the peptide may be partially degraded. If the desiccant is still active, the peptide is likely stable. Transfer to −20°C storage immediately upon receipt.

Check the freezer's temperature log if available. Most research-grade freezers record min/max temperatures. If the temperature rose above −10°C for more than 2 hours, assume 5–10% potency loss for lyophilized peptides and 15–25% loss for reconstituted aliquots. Peptides don't visually change after temperature excursions, so you can't rely on appearance. If the excursion was brief (under 1 hour above −10°C), potency loss is likely under 5%. For critical experiments, order fresh peptide rather than risk inconsistent results.

You can't. Not reliably. Reconstituted peptide solutions degrade in aqueous buffer regardless of refrigeration temperature. After 28 days at 2–8°C, expect 10–15% potency loss; after 60 days, expect 30–40% loss. If your research protocol requires peptide availability over several months, store the compound as lyophilised powder and reconstitute fresh 5–10mg aliquots every four weeks. This approach maintains consistent potency across your study timeline and eliminates batch-to-batch variability caused by progressive degradation in solution.

Discard it immediately. Cloudiness indicates either microbial contamination (if bacteriostatic water was compromised) or peptide aggregation due to improper storage pH or temperature. Neither is salvageable. Selank amidate solutions should remain crystal clear throughout the 28-day window. Any visible change (cloudiness, colour shift, particulates) is a hard stop. Do not attempt to filter or clarify the solution; aggregated peptides have altered pharmacokinetics and cannot be restored to native structure.

Use a portable medical cooler designed for peptide transport. Models like the FRIO wallet use evaporative cooling and maintain 2–8°C for 36–48 hours without ice or electricity. For lyophilized powder, pack the vial with gel ice packs (not loose ice, which introduces moisture) in an insulated container. Monitor temperature with a digital thermometer throughout transit. A single 6-hour excursion above 8°C for reconstituted DSIP can cause partial denaturation.

Use a medical-grade insulin cooler designed to maintain 2–8°C for 24–48 hours without ice or electricity. Products like the FRIO wallet use evaporative cooling and require only a one-time water activation to stay cold for up to two days. Place reconstituted vials inside the cooler with a small adhesive thermometer to monitor actual temperature during transit. Never pack peptides in checked luggage. Temperature in aircraft cargo holds can drop below freezing at altitude, which introduces freeze-thaw damage. Carry peptides in your cabin bag and store the cooler under the seat in front of you, not in the overhead bin where temperature fluctuates.

Do not use it. Freezing a reconstituted peptide solution causes ice crystal formation that physically disrupts peptide tertiary structure. The spatial folding that determines biological activity. When thawed, the solution may appear clear, but the peptide's functional shape has been irreversibly altered. This is why reconstituted peptides must never be stored in a freezer, even short-term.

Discard it immediately. Cloudiness indicates either bacterial contamination or peptide aggregation (clumping of peptide molecules), both of which render the solution unusable. Properly reconstituted DSIP should be clear and colourless. Aggregation occurs when peptides denature and their hydrophobic regions clump together. A sign that storage conditions failed.

Discard the vial immediately. Freezing aqueous peptide solutions forms ice crystals that physically shear peptide bonds and disrupt tertiary structure through mechanical stress. Once thawed, the solution may appear normal but SS-31's mitochondrial-targeting function will be severely compromised. Research from Caltech's peptide chemistry lab demonstrated that frozen-thawed aromatic peptides lose 60–85% binding affinity to target membranes even when concentration remains unchanged. There is no salvage protocol. Freezing reconstituted solutions is a terminal failure mode.

Discard it. Reconstituted peptide solution stored at room temperature for 8+ hours experiences significant structural degradation. Studies on similar D-amino acid peptides show 30–50% potency loss within 24 hours at 22°C. The peptide may still appear clear and unchanged, but bioactivity drops below therapeutic threshold. Attempting to salvage it by refrigerating after prolonged ambient exposure doesn't reverse the damage. Thermal denaturation is permanent. If the exposure was under four hours and the ambient temperature stayed below 18°C, you might retain partial activity, but there's no home test to verify potency. The financial cost of discarding one vial is lower than the research cost of using compromised peptide that produces unreliable results.

If unreconstituted lyophilised peptide was stored at 20–25°C for 48 hours, it has likely lost 5–10% potency but remains usable for most research protocols. Refrigerate or freeze it immediately and reconstitute within the next 8–12 weeks rather than storing it for months. The real risk is cumulative. If it sat at room temperature during shipping, then again at your facility, then experienced a power outage, you're stacking degradation events. If the vial seal was intact and the powder still appears dry and white (not clumped or discolored), proceed with reconstitution but treat the batch as lower-priority stock.

Discard it. A reconstituted peptide vial left at room temperature (20–25°C) for 8+ hours has undergone sufficient thermal degradation that bioactivity is unpredictable. Peptide bonds are susceptible to hydrolysis at elevated temperatures, and the process accelerates exponentially above 8°C. You cannot reverse this damage by refrigerating the vial afterward. The degradation already occurred. Using a thermally compromised peptide wastes research time and introduces uncontrolled variables. If you're uncertain about the exposure duration, err on the side of discarding it.

Discard it. LL-37 loses 30–40% potency after 24 hours at room temperature due to methionine oxidation. The peptide may still appear clear and soluble, but antimicrobial activity against S. aureus and E. coli drops measurably within 12 hours at 20–25°C. The oxidised peptide cannot be restored. Refrigeration after room-temperature exposure does not reverse structural damage.

Lyophilized peptide can travel in carry-on luggage at ambient temperature for up to 48 hours. Pack it in its original sealed vial inside a protective case. Reconstituted peptide requires a medical-grade cooler (FRIO or equivalent) that maintains 2–8°C without ice. Standard TSA rules allow medically necessary cooling devices; bring documentation if asked. Never check reconstituted peptide in luggage. Cargo holds can reach 35°C+ on tarmacs, which destroys peptide activity within two hours.

Use an insulated cooler with gel ice packs preconditioned to 2–8°C (not frozen solid. Frozen packs can drop the internal temperature below 0°C). Transport time should not exceed 6 hours. Include a calibrated temperature logger to verify the vial stayed within range. If temperature exceeded 15°C at any point, potency cannot be guaranteed. Repeat antimicrobial assays before using in experiments.

Discard it immediately. Cloudiness in previously clear peptide solution indicates either protein aggregation or microbial contamination. Both render the compound unusable. Aggregation occurs when peptides clump together into large, insoluble complexes that no longer interact with cellular targets. This can result from temperature cycling, pH shifts, or excessive agitation. Contamination-related cloudiness means bacterial or fungal growth has occurred despite the bacteriostatic water preservative, which happens when contamination levels exceed the preservative's inhibitory capacity. Neither condition is reversible, and administering aggregated or contaminated peptide poses safety risks. The proper response is disposal and reconstitution of a fresh vial using stricter sterile technique to prevent recurrence.

Use a validated cold-chain container that maintains 2–8°C for the entire transit duration. Standard insulin coolers or medical specimen transport bags with gel ice packs work for trips under six hours. Place the vial in the centre of the container surrounded by pre-chilled packs, and include a min-max thermometer to verify the temperature stayed within range. For longer transports, purpose-built peptide shipping containers with phase-change materials maintain stable cold temperatures for 24–48 hours. Never place the vial directly against ice packs. Direct contact can freeze portions of the solution. Wrap the vial in bubble wrap or foam to insulate it from temperature extremes while allowing passive cooling. If transporting across climates with ambient temperatures above 30°C, use active cooling systems rather than passive ice packs to prevent thermal overload.